Ignite Creation Date:
2025-12-24 @ 3:02 PM
Ignite Modification Date:
2025-12-25 @ 4:12 PM
Study NCT ID:
NCT03991559
Status:
UNKNOWN
Last Update Posted:
2019-08-28
First Post:
2019-06-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009362', 'term': 'Neoplasm Metastasis'}], 'ancestors': [{'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D009385', 'term': 'Neoplastic Processes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C025340', 'term': 'manganese chloride'}, {'id': 'C000711728', 'term': 'spartalizumab'}, {'id': 'D000082082', 'term': 'Immune Checkpoint Inhibitors'}], 'ancestors': [{'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D020228', 'term': 'Pharmacologic Actions'}, {'id': 'D020164', 'term': 'Chemical Actions and Uses'}, {'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'}, {'id': 'D000970', 'term': 'Antineoplastic Agents'}, {'id': 'D045506', 'term': 'Therapeutic Uses'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 20}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2018-11-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-08', 'completionDateStruct': {'date': '2020-05-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-08-27', 'studyFirstSubmitDate': '2019-06-14', 'studyFirstSubmitQcDate': '2019-06-18', 'lastUpdatePostDateStruct': {'date': '2019-08-28', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-06-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Subjects with treatment-related adverse events (AEs)', 'timeFrame': 'Approximately 6 months', 'description': 'Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0. AEs were considered to be treatment-related if they had started or worsened within the interval from first study drug administration until the follow-up visit.'}, {'measure': 'Number of subjects with specific Manganese-related adverse events', 'timeFrame': 'Approximately 6 months', 'description': 'Manganese-related AEs were considered to be that start or worsen after administration Manganese administration，improve after withdrawal, and even occur again after re-administration.'}], 'secondaryOutcomes': [{'measure': 'Preliminary efficacy evaluation', 'timeFrame': 'Approximately 6 months', 'description': 'Objective response rate (ORR) and disease control rate (DCR) will be evaluated by investigators per the RECIST V1.1.'}, {'measure': 'The q3w pharmacokinetic profile of Manganese', 'timeFrame': 'Approximately 3 months', 'description': 'PK parameters such as Maximum concentration (Cmax) are assessed.'}, {'measure': 'Number of participants with laboratory test abnormalities', 'timeFrame': 'Approximately 3 months', 'description': 'The laboratory tests of serum cytokines and chemokines will be performed on day 1 and 3 of each cycle, and the abnormality will be determined by the investigator.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['anti-PD-1 antibody', 'Manganese', 'unresectable', 'metastatic'], 'conditions': ['Solid Tumor', 'Lymphoma']}, 'descriptionModule': {'briefSummary': 'Identification of T cell inhibitory signals, including PD-1/PD-L1, has prompted the development of a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. However, elimination of cancer by T cells is only one step in the Cancer-Immunity Cycle, which enable providing several therapeutic targets and tailoring of combinations of immune therapies. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This study is a first-in-man, Phase I, 3 + 3 dose escalation study of a combined regimen of Manganese and anti-PD-1 antibody with or without chemotherapies in subjects with unresectable/ metastatic solid tumors or lymphomas. This study is designed to assess the safety, tolerability, pharmacokinetic profile (PK profile), mode of delivery and Recommended Phase 2 Dose (RP2D) of this regimen.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Subjects must have histologically proven unresectable/ metastatic solid tumors or lymphomas.\n2. ≥ 18 years old.\n3. Life expectancy of at least 6 months.\n4. Eastern Cooperative Oncology Group performance status 0-2.\n5. Subjects must have at least one measurable lesion ≥ 1 cm as defined by response criteria.\n6. Subjects must have received at least two frontline therapies, except for patients initially diagnosed with local advanced or metastatic pancreatic cancer or cholangiocarcinoma.\n7. Subjects must be off prior therapy for at least 4 weeks prior to Day 1. Subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months. Subjects with Anti-PD-1 antibody are eligible which must be resistance.\n8. Adequate organ function.\n9. Participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug.\n\nExclusion Criteria:\n\n1. Subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications.\n2. Serious uncontrolled medical disorders or active infections, pulmonary infection especially.\n3. T cell lymphomas or leukemia.\n4. Prior organ allograft.\n5. Women who are pregnant or breastfeeding.\n6. Women with a positive pregnancy test on enrollment or prior to investigational product administration.\n7. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.'}, 'identificationModule': {'nctId': 'NCT03991559', 'briefTitle': 'A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas', 'organization': {'class': 'OTHER', 'fullName': 'Chinese PLA General Hospital'}, 'officialTitle': 'A Phase I, Two-arm, Open-label, Single-center, Dose-escalation Study to Evaluate the Safety, Tolerability and Recommended Dose and Delivery Mode of the Pan-immunotherapy in Subjects With Unresectable/ Metastatic Solid Tumors or Lymphomas', 'orgStudyIdInfo': {'id': 'CHN-PLAGH-BT-039'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Dose-Escalation, intranasally', 'description': 'With a standard 3+3 dose escalation design, the enrollment will proceed until the maximum tolerated dose (MTD) has been defined or the highest dose level has been reached.', 'interventionNames': ['Drug: Manganese Chloride', 'Drug: Anti-PD-1 antibody', 'Combination Product: Systemic therapy']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Dose-Escalation, inhalation', 'description': 'With a standard 3+3 dose escalation design, the enrollment will proceed until the MTD has been defined or the highest dose level has been reached.', 'interventionNames': ['Drug: Manganese Chloride', 'Drug: Anti-PD-1 antibody', 'Combination Product: Systemic therapy']}], 'interventions': [{'name': 'Manganese Chloride', 'type': 'DRUG', 'description': 'Administered intranasally in Arm 1 (0.05, 0.1 or 0.2 mg/kg/d) and by inhalation in Arm 2 (0.1, 0.2 or 0.4mg/kg/d) once daily in a 3-week cycle', 'armGroupLabels': ['Dose-Escalation, inhalation', 'Dose-Escalation, intranasally']}, {'name': 'Anti-PD-1 antibody', 'type': 'DRUG', 'otherNames': ['Anti-PD-1 monoclonal antibody', 'PD-1 inhibitor'], 'description': 'Administered intravenously, at 2-4mg/kg on day 3 in a 3-week cycle', 'armGroupLabels': ['Dose-Escalation, inhalation', 'Dose-Escalation, intranasally']}, {'name': 'Systemic therapy', 'type': 'COMBINATION_PRODUCT', 'description': 'Whether and which should be given depends on the treatment regimen before enrollment.', 'armGroupLabels': ['Dose-Escalation, inhalation', 'Dose-Escalation, intranasally']}]}, 'contactsLocationsModule': {'locations': [{'zip': '100853', 'city': 'Beijing', 'state': 'Beijing Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Weidong Han, M.D', 'role': 'CONTACT', 'email': 'hanwdrsw@sina.com', 'phone': '+86-10-66937463'}, {'name': 'Qingming Yang, M.D', 'role': 'CONTACT', 'email': 'yangqm301@163.com', 'phone': '+86-10-55499341'}, {'name': 'Weidong Han, M.D', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Qian Mei, M.D', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Qingming Yang, M.D', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Meixia Chen, M.S', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Yan Zhang, M.S', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Kaichao Feng, M.S', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Yang Liu, M.D.', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Jiejie Liu, B.S', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Xiang Li, B.S', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Liang Dong, B.S', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'Biotherapeutic Department of Chinese PLA General Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}], 'centralContacts': [{'name': 'Weidong Han, M.D.', 'role': 'CONTACT', 'email': 'hanwdrsw@sina.com', 'phone': '+861066937463'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Chinese PLA General Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Han weidong', 'investigatorAffiliation': 'Chinese PLA General Hospital'}}}}